Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care [0.03%]
refractory 微卫星稳定型转移性结直肠癌：Botensilimab+Balstilimab与当前标准治疗的比较
E Bengala,D Santini,V Picone
E Bengala
Background: The combination of botensilimab + balstilimab demonstrated promising clinical activity in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer (mCRC) in a recently published pha...
Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells [0.03%]
V区Ig含T细胞活化抑制分子和程序性死亡-1配体的相互作用可抑制T细胞的抗癌活性
M Abooali,X Lei,I M Yasinska et al.
M Abooali et al.
Background: V-domain immunoglobulin-containing suppressor of T cell activation (VISTA) is a unique multifunctional immune checkpoint protein, which can display both receptor and ligand properties. It plays a crucial role ...
Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial [0.03%]
一项关于尼伏单抗联合减分数放疗治疗黏膜黑色素瘤患者的II期研究——PORTER-M3试验
M Nomura,M Yoshimura,T Yokota et al.
M Nomura et al.
Background: The response rate of nivolumab monotherapy for mucosal melanoma is only ∼20%. The objective of this phase II trial was to evaluate the efficacy and safety of nivolumab in combination with radiotherapy for met...
Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab [0.03%]
用于转移性脉络膜黑色素瘤患者的孤立肝灌注联合伊匹木单抗和纳武利尤单抗治疗的纵向ctDNA监测
M Kadefors,A Nelson,E Blomberg et al.
M Kadefors et al.
Background: Uveal melanoma (UM) is a rare cancer, which often metastasizes to the liver, leading to a poor prognosis. In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with iso...
Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression [0.03%]
高PD-L1表达非小细胞肺癌患者中肿瘤内菌群与免疫治疗疗效相关性研究
F Shoji,T Kawabata,K Kosai et al.
F Shoji et al.
Background: High expression of tumoral programmed death-ligand 1 (PD-L1) [high PD-L1 tumor proportion score (TPS)] is a predictive biomarker of response to cancer immunotherapy in lung cancer; however, its predictiveness ...
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients [0.03%]
转移病灶影响四期黑色素瘤患者的疾病进展模式和生存期
I A Vergara,S N Lo,I Li et al.
I A Vergara et al.
Background: Metastatic sites influence response rates to immune checkpoint inhibitors (ICI) and survival, suggesting anatomical locations impact treatment outcomes. This study examines how baseline metastatic sites affect...
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy [0.03%]
TCR谱型的利用：肿瘤免疫治疗中的预测性和治疗监测能力
J Chiffelle,R Genolet,O Michielin et al.
J Chiffelle et al.
The T-cell receptor (TCR) repertoire, representing the vast diversity of T cells, is a cornerstone of adaptive immunity and a powerful tool in oncology. Advances in high-throughput sequencing have enabled deep profiling of TCR diversity and...
O Menyhart,B Győrffy
O Menyhart
Background: Immune evasion is a hallmark of cancer and a driver of therapeutic resistance. Although immunotherapy is effective in highly immunogenic cancers, its efficacy in breast cancer (BC) remains limited. We aimed to...
Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives [0.03%]
蛋白工程克服细胞因子在癌症免疫治疗中的限制：目前的策略和未来的展望
U Salazar,P Cioffi,B Taskoparan et al.
U Salazar et al.
Given their central role in immune regulation, cytokines have long been considered attractive therapeutic agents, particularly in cancer immunotherapy. Despite a strong preclinical and clinical rationale, only a limited number of cytokines ...
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages [0.03%]
涵盖各类乳腺癌亚型和疾病阶段的系统性免疫全景分析
N A M Bakker,H Garner,V C M Geurts et al.
N A M Bakker et al.
Background: Breast cancer is a systemic disease, yet the impact of tumor molecular subtype and disease stage on the systemic immune landscape remains poorly understood. In this study, we comprehensively analyzed the syste...